B-VEC
4 July 2023

ABSTRACT: Compassionate use of topical beremagene geperpavec (B-VEC) for the treatment of recurrent cicatrizing conjunctivitis in a patient with dystrophic epidermolysis bullosa

Keywords: B-VEC, Krystal, Opthalmology, Gene therapy
31 January 2024

Estimated Spending on Beremagene Geperpavec for Dystrophic Epidermolysis Bullosa

JAMA Dermatol. 2024 Jan 31. doi: 10.1001/jamadermatol.2023.5857. Epub ahead of print. PMID: 38294784; PMCID: PMC10831624. Estimated Spending on Beremagene Geperpavec for Dystrophic Epidermolysis Bullosa Authors: Adam […]